HOME >> BIOLOGY >> NEWS
Acorda Therapeutics begins Phase 3 trials of Fampridine-SR for chronic spinal cord injury

Hawthorne, NY June 28, 2002 Acorda Therapeutics announced today that it has begun two Phase 3 clinical studies of its lead product, Fampridine-SR, in chronic spinal cord injury. The trials will evaluate the safety and efficacy of Fampridine-SR in the treatment of moderate-to-severe spasticity associated with chronic SCI. Spasticity, which affects up to 75% of people with chronic SCI, manifests itself as involuntary stiffness or contraction of muscles.

The studies will enroll a total of 360 patients at more than 70 of the leading spinal cord injury (SCI) clinical centers in the United States and Canada. Individuals who are interested in finding out about participating in these studies may call 866-206-2322, toll-free, weekdays from 9:00 a.m. (EDT) to 7:00p.m. (EDT)

"There is significant demand for new treatment options in chronic spinal cord injury, especially spasticity. Spasticity is a serious complication of SCI that frequently interferes with movement and daily activities, and can cause severe pain or injury," said Ron Cohen, MD, Acorda's President and Chief Executive Officer.

Fampridine ("4-aminopyridine", "4-AP") enhances conduction in damaged nerves, and is the first compound shown to restore some neurological function to people with SCI. Fampridine-SR is an oral, sustained-release formulation of fampridine, designed for twice-daily dosing. The drug restores nerve conduction by blocking exposed potassium channels in demyelinated nerve processes, or axons. Fampridine-SR is also in Phase 2 clinical trials to evaluate safety and efficacy in the treatment of symptoms associated with multiple sclerosis (MS).

In previous SCI clinical trials, administration of Fampridine-SR has been shown to reduce spasticity, and to improve sexual function and bowel and bladder control. The most common side effects observed with Fampridine-SR treatment have been pain, paresthesia, insomnia, dizziness, constipation, and nausea. At clin
'"/>


1-Jul-2002


Page: 1 2

Related biology news :

1. Acorda therapeutics receives NIH Phase 2 grant for central nervous system repair
2. Acorda Therapeutics acquires CeNeS neuregulin products
3. Acorda Therapeutics receives L.W. Freeman Award for Scientific Research
4. 16th EORTC NCI AACR Symposium Molecular Targets and Cancer Therapeutics
5. 16th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
6. PTC Therapeutics researchers identify biochemical pathway important for modulating cell growth
7. Critical Therapeutics announces issuance of US patent for novel anti-inflammatory technology
8. Medimmune and Critical Therapeutics to co-develop treatments for severe inflammatory diseases
9. Immerge BioTherapeutics announces new findings addressing key safety risk in xenotransplantation
10. Critical Therapeutics launches Phase I clinical trial of anti-inflammatory compound
11. Immerge BioTherapeutics announces identification of PERV receptor

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/14/2017)... (NYSE: IBM ) is introducing several innovative partner startups ... collaboration between startups and global businesses, taking place in ... nine startups will showcase the solutions they have built with ... France is one of the ... percent increase in the number of startups created between 2012 ...
(Date:5/16/2017)... 16, 2017   Bridge Patient Portal , ... MD EMR Systems , an electronic medical ... GE, have established a partnership to build an ... the GE Centricity™ products, including Centricity Practice Solution ... These new integrations will allow healthcare delivery ...
(Date:4/19/2017)... New York , April 19, 2017 ... competitive, as its vendor landscape is marked by the ... the market is however held by five major players ... Safran. Together these companies accounted for nearly 61% of ... of the leading companies in the global military biometrics ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... ... platform specifically designed for life science researchers to analyze and interpret datasets, ... Franklin, who made a major contribution to the discovery of the double-helix ...
(Date:10/11/2017)... ... ... Personal eye wash is a basic first aid supply for any work environment, but most ... you rinse first if a dangerous substance enters both eyes? It’s one less decision, and ... unique dual eye piece. , “Whether its dirt and debris, or an acid or alkali, ...
(Date:10/11/2017)... , Oct. 11, 2017  VMS BioMarketing, a leading ... a nationwide oncology Clinical Nurse Educator (CNE) network, which will ... need for communication among health care professionals to enhance the ... nurses, office staff, and other health care professionals to help ... breast cancer. ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... implantation and pregnancy rates in frozen and fresh in vitro fertilization (IVF) ... and maternal age to IVF success. , After comparing the results from the ...
Breaking Biology Technology:
Cached News: